Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, People's Republic of China.
Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, People's Republic of China.
Biomed Pharmacother. 2019 Oct;118:109202. doi: 10.1016/j.biopha.2019.109202. Epub 2019 Aug 19.
IFC-305, an adenosine derivative, has been proved to exert a therapeutic effect on radiation-induced intestinal toxicity in colon cancer (CC). The aim of the present study was to investigate the underlying molecular mechanism of protective role of IFC-305 in CC by modifying the methylation of peroxisome proliferator-activated receptor (PPAR)-r promoter.
Peripheral blood and cancerous tissues samples were collected from the CC patients. Irradiation (IR) mice models were established in comparison with control mice accordingly. Bisulfite sequencing, real-time PCR, Western-blot analysis, immunohistochemistry (IHC) and hematoxylin eosin (HE) staining were performed upon both human and animal samples.
The results upon the human CC samples demonstrated that the level of methylation of PPAR-r promoter in methylated patients was increased, while the risk of radiation-induced intestinal toxicity in methylated patients was also increased compared with unmethylated patients. Also, the PPAR-r mRNA/protein expression was lower in methylated patients compared with unmethylated patients, thus indicating the presence of PPAR-r promoter methylation repressed PPAR-r expression in vivo. Moreover, in the mice models, IFC-305 treatment partially alleviated radiation-induced toxicity in the columnar epithelia and tubular glands of IR mice, and villus height and the number/circumference of crypts were also increased while the relative number of inflammatory cells was decreased in IR + IFC-305 mice group compared with the control mice. Compared with the control group, the levels of PPAR-r mRNA/protein expression were significantly decreased in IR mice, while the presence of IFC-305 exerted therapeutic effect upon IR rats via elevating the PPAR-r mRNA/protein expression to a certain extent.
In this study, we demonstrated the relationship between PPAR-r promoter methylation and the risk of radiation-induced intestinal toxicity via studying the clinical samples collected from CC patients. And the study upon mice models suggested that the administration of IFC-305 could alleviate radiation-induced intestinal toxicity through decreasing the methylation of PPAR-r promoter and enhancing the expression of PPAR-r in IR mice.
IFC-305 是一种腺嘌呤衍生物,已被证明可对结肠癌(CC)的辐射诱导的肠道毒性发挥治疗作用。本研究的目的是通过修饰过氧化物酶体增殖物激活受体(PPAR)-r 启动子的甲基化来研究 IFC-305 在 CC 中发挥保护作用的潜在分子机制。
收集 CC 患者的外周血和癌组织样本。相应地,建立照射(IR)小鼠模型并与对照小鼠进行比较。对人及动物样本进行亚硫酸氢盐测序、实时 PCR、Western blot 分析、免疫组织化学(IHC)和苏木精-伊红(HE)染色。
对人 CC 样本的研究结果表明,甲基化患者 PPAR-r 启动子的甲基化水平增加,与非甲基化患者相比,甲基化患者发生辐射诱导的肠道毒性的风险也增加。此外,与非甲基化患者相比,甲基化患者的 PPAR-rmRNA/蛋白表达水平较低,这表明体内 PPAR-r 启动子甲基化抑制了 PPAR-r 的表达。此外,在小鼠模型中,IFC-305 治疗部分缓解了 IR 小鼠柱状上皮和管状腺的辐射毒性,IR+IFC-305 小鼠组的绒毛高度和隐窝数量/周长增加,而炎症细胞的相对数量减少。与对照组相比,IR 小鼠的 PPAR-rmRNA/蛋白表达水平显著降低,而 IFC-305 的存在通过在一定程度上提高 PPAR-rmRNA/蛋白表达对 IR 大鼠发挥治疗作用。
在这项研究中,我们通过研究从 CC 患者收集的临床样本,证明了 PPAR-r 启动子甲基化与辐射诱导的肠道毒性风险之间的关系。在小鼠模型上的研究表明,IFC-305 的给药可通过降低 PPAR-r 启动子的甲基化并增强 IR 小鼠中 PPAR-r 的表达来减轻辐射诱导的肠道毒性。